Literature DB >> 8178492

HIV-2 and SIV infection of nonprimate cell lines expressing human CD4: restrictions to replication at distinct stages.

A McKnight1, P R Clapham, R A Weiss.   

Abstract

Mouse, rat, rabbit, cat, and mink cell lines expressing human CD4 restrict entry of HIV-1 strains at the cell surface. We now report that CD4+ cat and rabbit cell lines are permissive to cell fusion induced by several HIV-2 and SIV strains. CD4+ rat and mouse cells are only sensitive to HIV-2 and SIV fusion in the presence of active amphotericin B. HIV-2 and SIV replicate in CD4+ cat and CD4+ mink cells, but not in the CD4+ rabbit, rat, or mouse cells. These latter cell lines poorly express a transfected DNA molecular clone of HIV-2 DNA. CD4+ rat cells are sensitive to entry by HIV-2 (HTLV-1) pseudotypes and also to HIV-2 if amphotericin B is present. Early reverse transcription then occurs without subsequent viral gene expression, but the fusion-sensitive CD4+ rabbit cells are not permissive for HIV-2 reverse transcription. Our observations demonstrate (i) that the cat and mink cell lines express everything required except human CD4 for entry and replication by several HIV-2 and SIV strains and (ii) that distinct postpenetration blocks to viral replication are evident in rabbit and rodent cell lines.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8178492     DOI: 10.1006/viro.1994.1260

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  36 in total

1.  Promiscuous use of CC and CXC chemokine receptors in cell-to-cell fusion mediated by a human immunodeficiency virus type 2 envelope protein.

Authors:  R Bron; P J Klasse; D Wilkinson; P R Clapham; A Pelchen-Matthews; C Power; T N Wells; J Kim; S C Peiper; J A Hoxie; M Marsh
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Usage of the coreceptors CCR-5, CCR-3, and CXCR-4 by primary and cell line-adapted human immunodeficiency virus type 2.

Authors:  N Sol; F Ferchal; J Braun; O Pleskoff; C Tréboute; I Ansart; M Alizon
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development.

Authors:  Antonella Castagna; Priscilla Biswas; Alberto Beretta; Adriano Lazzarin
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Characterization of a late entry event in the replication cycle of human immunodeficiency virus type 2.

Authors:  D J Griffiths; M Dittmar; P Clapham; E Thomas
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 5.  Retroviral restriction and dependency factors in primates and carnivores.

Authors:  Hind J Fadel; Eric M Poeschla
Journal:  Vet Immunol Immunopathol       Date:  2011-06-12       Impact factor: 2.046

6.  Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein.

Authors:  A McKnight; C Shotton; J Cordell; I Jones; G Simmons; P R Clapham
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

7.  Possible role of the V3 domain of gp120 in resistance to an amphotericin B derivative (MS8209) blocking human immunodeficiency virus entry.

Authors:  O Pleskoff; N Sol; H Marrakchi; M Serlin; M Seman; M Alizon
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

8.  The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion.

Authors:  J D Reeves; T F Schulz
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

9.  Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239.

Authors:  L Marcon; H Choe; K A Martin; M Farzan; P D Ponath; L Wu; W Newman; N Gerard; C Gerard; J Sodroski
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

10.  Interferon-alpha mediates restriction of human immunodeficiency virus type-1 replication in primary human macrophages at an early stage of replication.

Authors:  Kelly M Cheney; Áine McKnight
Journal:  PLoS One       Date:  2010-10-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.